Zhejiang Jingxin Pharmaceutical Co Ltd (002020) - Total Liabilities
Based on the latest financial reports, Zhejiang Jingxin Pharmaceutical Co Ltd (002020) has total liabilities worth CN¥1.91 Billion CNY (≈ $280.12 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Zhejiang Jingxin Pharmaceutical Co Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
Zhejiang Jingxin Pharmaceutical Co Ltd - Total Liabilities Trend (2001–2025)
This chart illustrates how Zhejiang Jingxin Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Zhejiang Jingxin Pharmaceutical Co Ltd (002020) total assets.
Zhejiang Jingxin Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Jingxin Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wuxi Paike New Materials Technology Co Ltd
SHG:605123
|
China | CN¥4.24 Billion |
|
Sobha Limited
NSE:SOBHA
|
India | Rs-47.20 Billion |
|
Wolfspeed, Inc.
NYSE:WOLF
|
USA | $2.07 Billion |
|
Nanjing Hanrui Cobalt Co Ltd
SHE:300618
|
China | CN¥4.75 Billion |
|
Guangdong Homa Appliances Co Ltd
SHE:002668
|
China | CN¥10.64 Billion |
|
Shanghai Liangxin Electrical Co Ltd
SHE:002706
|
China | CN¥1.91 Billion |
|
BH Macro Limited
LSE:BHMG
|
UK | £5.84 Million |
|
Zhejiang Fulai New Material Co.Ltd.
SHG:605488
|
China | CN¥1.98 Billion |
Liability Composition Analysis (2001–2025)
This chart breaks down Zhejiang Jingxin Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Zhejiang Jingxin Pharmaceutical Co Ltd to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Jingxin Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Jingxin Pharmaceutical Co Ltd (2001–2025)
The table below shows the annual total liabilities of Zhejiang Jingxin Pharmaceutical Co Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.25 Billion ≈ $329.72 Million |
-9.06% |
| 2024-12-31 | CN¥2.48 Billion ≈ $362.58 Million |
+1.28% |
| 2023-12-31 | CN¥2.45 Billion ≈ $357.99 Million |
+11.68% |
| 2022-12-31 | CN¥2.19 Billion ≈ $320.55 Million |
+38.85% |
| 2021-12-31 | CN¥1.58 Billion ≈ $230.87 Million |
-8.99% |
| 2020-12-31 | CN¥1.73 Billion ≈ $253.68 Million |
-9.44% |
| 2019-12-31 | CN¥1.91 Billion ≈ $280.13 Million |
+34.97% |
| 2018-12-31 | CN¥1.42 Billion ≈ $207.55 Million |
+51.14% |
| 2017-12-31 | CN¥938.43 Million ≈ $137.32 Million |
+8.59% |
| 2016-12-31 | CN¥864.23 Million ≈ $126.46 Million |
+27.21% |
| 2015-12-31 | CN¥679.39 Million ≈ $99.42 Million |
+1.99% |
| 2014-12-31 | CN¥666.12 Million ≈ $97.47 Million |
+31.47% |
| 2013-12-31 | CN¥506.65 Million ≈ $74.14 Million |
-4.12% |
| 2012-12-31 | CN¥528.40 Million ≈ $77.32 Million |
+23.92% |
| 2011-12-31 | CN¥426.39 Million ≈ $62.39 Million |
-32.21% |
| 2010-12-31 | CN¥629.02 Million ≈ $92.05 Million |
+3.11% |
| 2009-12-31 | CN¥610.06 Million ≈ $89.27 Million |
-6.13% |
| 2008-12-31 | CN¥649.89 Million ≈ $95.10 Million |
-9.26% |
| 2007-12-31 | CN¥716.18 Million ≈ $104.80 Million |
+49.76% |
| 2006-12-31 | CN¥478.23 Million ≈ $69.98 Million |
+71.24% |
| 2005-12-31 | CN¥279.27 Million ≈ $40.87 Million |
+54.20% |
| 2004-12-31 | CN¥181.11 Million ≈ $26.50 Million |
+6.31% |
| 2003-12-31 | CN¥170.36 Million ≈ $24.93 Million |
+42.74% |
| 2002-12-31 | CN¥119.35 Million ≈ $17.46 Million |
+6.73% |
| 2001-12-31 | CN¥111.83 Million ≈ $16.36 Million |
-- |
About Zhejiang Jingxin Pharmaceutical Co Ltd
Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China and internationally. The company offers antihypertensive, antibiotics, quinolones, gastrointestinal promotion, antidiabetic, antiepileptic, antihistamine, H+ pump depressant, antihyper cholesterolemia, histamine H2 receptor blockader, antihyper cholesterolemi… Read more